8 reports of this reaction
2.7% of all ACETAMINOPHEN AND IBUPROFEN reports
#9 most reported adverse reaction
HYPERSENSITIVITY is the #9 most commonly reported adverse reaction for ACETAMINOPHEN AND IBUPROFEN, manufactured by AFT Pharmaceuticals US, Inc.. There are 8 FDA adverse event reports linking ACETAMINOPHEN AND IBUPROFEN to HYPERSENSITIVITY. This represents approximately 2.7% of all 299 adverse event reports for this drug.
Patients taking ACETAMINOPHEN AND IBUPROFEN who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is a less commonly reported adverse event for ACETAMINOPHEN AND IBUPROFEN, but still significant enough to appear in the safety profile.
In addition to hypersensitivity, the following adverse reactions have been reported for ACETAMINOPHEN AND IBUPROFEN:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 8 FDA reports for ACETAMINOPHEN AND IBUPROFEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 2.7% of all adverse event reports for ACETAMINOPHEN AND IBUPROFEN, making it a notable side effect.
If you experience hypersensitivity while taking ACETAMINOPHEN AND IBUPROFEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.